Page 6,602«..1020..6,6016,6026,6036,604..6,6106,620..»

Fresh cell therapy promises better health, sex and more

Posted: Published on August 14th, 2012

MANILA, Philippines Celebrity hairstylist Ricky Reyes, talent manager and host Lolit Solis, actress Lorna Tolentino and even former President Joseph Estrada are only among the prominent Filipinos who swear by the healing effects of fresh cell therapy, which involves the injection of live animal cells into the body. Reyes, who used to suffer from a rare disease which he called reading eye epilepsy, said he went to Germany last June for fresh cell therapy. After a number of sessions, the celebrity hairstylist can now read newspapers without suffering a seizure. It was gone immediately, he said. Pati arthritis ko. Naalis yung sakit, tapos gaganda at babata ka pa. Solis, 65, had fresh cell therapy after experiencing knee pain, and 75-year-old Estrada opted to undergo the procedure in Germany to keep healthy. Before them, several other well-known figures worldwide are said to have tried fresh cell treatments, among them the late English actor Charlie Chaplin. So how is this procedure done? Dr. Robert Janson-Muller, who runs a fresh cell therapy clinic in Germany, is in town to give Filipinos the lowdown on this decades-long treatment. Not stem cell treatment Before starting his lecture for members of the local media on Tuesday, … Continue reading

Comments Off on Fresh cell therapy promises better health, sex and more

NeoStem Announces Quarterly Results and Business Update

Posted: Published on August 14th, 2012

NEW YORK, Aug. 14, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company") today announced second quarter results and provided a business update. NeoStem is rapidly emerging as a market leader in the fast growing cell therapy market. The Company's multifaceted business strategy combines a state-of-the-art contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program providing for near- and long-term revenue growth opportunities. Business Highlights Progress Report on Erye Divestiture As of today, NeoStem has received directly or into escrow $6.2 million representing 50% of the total $12.3 million cash purchase price. The divestiture of Erye will also return approximately 1,040,000 shares of the Company's Common Stock and cancel 1,170,000 Common Stock options and 640,000 Common Stock warrants. In addition to receiving $12.3 million in cash to use towards U.S. operations, the divestiture will bolster NeoStem's balance sheet by eliminating over $35 million in short- and long-term debt obligations. The divestiture transaction is expected to close in the next 6-10 weeks, subject to the satisfaction of various closing conditions including China regulatory approvals, the submission of which is already underway. The Company's second quarter results include Erye, its Pharmaceutical Manufacturing -- … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on NeoStem Announces Quarterly Results and Business Update

Stemedica International Receives Licenses From Swissmedic for Import and Export of Its Stemedyne(TM) Stem Cell Line

Posted: Published on August 14th, 2012

EPALINGES, Switzerland, Aug. 14, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Stemedica International, SA (Epalinges, Switzerland), a wholly owned subsidiary of Stemedica Cell Technologies, Inc. ("Stemedica"), a leader in adult stem cell research and manufacturing, announced today that it has been granted a series of licenses by Swissmedic (the Swiss equivalent of the United States Food and Drug Administration). These licenses specifically authorize the Company to import and export its Stemedyne(TM) stem cell products worldwide for human use in approved clinical trials. Granting of the license by Swissmedic marks the culmination of a two-year inspection process of Stemedica's United States and Swiss operations. The Swiss government's rigorous inspection and approval process has included: (1) a comprehensive, in-depth audit of Stemedica's processes and procedures; (2) the examination of Stemedica's quality systems; and (3) interviews with facility management and onsite inspections of the facilities. Stemedica currently produces two lines of ischemia-tolerant adult allogeneic stem cell products. These include Stemedyne(TM)-MSC, bone marrow derived mesenchymal stem cells and Stemedyne(TM)-NSC, neural stem cells. A third product, Stemedyne(TM) Retinal Pigment Epithelium (RPE) stem cells is currently in development. Stemedica now has full regulatory approval from the Swiss government to provide these cells to countries that can … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Stemedica International Receives Licenses From Swissmedic for Import and Export of Its Stemedyne(TM) Stem Cell Line

ReNeuron Group plc – Stroke Trial Update

Posted: Published on August 14th, 2012

ReNeuron Group (Berlin: RQE.BE - news) plc ("ReNeuron" or the "Company") ReNeuron receives DSMB clearance to progress to higher dose in stem cell clinical trial in stroke patients First (OTC BB: FSTC.OB - news) patient treated in this higher dose cohort Guildford, UK, 14 August 2012: ReNeuron Group plc (AIM: RENE) today provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition. The Company is pleased to report that the independent Data Safety Monitoring Board (DSMB) for the clinical trial has recommended that the trial advances to the evaluation of a higher dose of ReN001 in the third of four dose cohorts to be treated in the study. In arriving at this recommendation, the DSMB reviewed safety data from the first two dose cohorts of six patients treated with ReN001. Of these patients, two are through 18 month follow-up, one is through 12 … Continue reading

Comments Off on ReNeuron Group plc – Stroke Trial Update

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Posted: Published on August 14th, 2012

LONDON (ShareCast) - Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we make our plans for a subsequent Phase II clinical trial application with ReNeuron's ReN001 cell-based treatment for stroke disability,' said ReNeuron's Chief Executive Michael Hunt. The therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke. The group also announced that one patient in the trial has now been successfully treated with ReN001 and discharge from hospital with no acute safety issues arising. Shares jumped 14.91% to 3.7p. Speech recognition and payment solutions group Eckoh (LSE: ECK.L - news) has secured a two-year contract with UK baby website Kiddicare to provide secure card payment services over the phone. "This is the second EckohPROTECT contract to be secured in quick succession through the new referral agreement with a global service provider that was announced in May 2012," the firm said. Shares were up 7.84% at 13.75p. … Continue reading

Comments Off on Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

LifeCell gets 50,000 customers in stem cells banking

Posted: Published on August 14th, 2012

Chennai, Aug 14 (IBNS) Stem cells derived from the umbilical cord are known to have the potential to treat over 75 serious medical conditions. To enhance awareness, LifeCell partnered with model and actor Lisa Ray, who had undergone successful stem cell therapy for treatment of blood cancer. Lisa continues to endorse the brand. Whilst India is the worlds largest birthing country, the penetration of the stem cell storage has been a dismal 0.2pc compared to the global average which is between 5pc in the US to as high as 25pc in Singapore. LifeCell said it believes that poor awareness rate and per capita income are the primary reasons for low penetration in the Indian market, yet is optimistic that India would soon reach the global benchmarks. Mayur Abhaya, Managing Director and CEO said, When we launched our services in 2004 the medical fraternity was not even aware of the concept of stem cell banking. It was our responsibility to create awareness amongst both the doctors and the expectant parents about its enormous scope in the future." The stem cell storage industry is growing at a rate of 30-40pc per year. More and more innovative services have been launched in the … Continue reading

Comments Off on LifeCell gets 50,000 customers in stem cells banking

Autism advocate Temple Grandin in Arkansas

Posted: Published on August 14th, 2012

(ROBYN BECK/AFP/Getty Images) LITTLE ROCK, Ark. (KTHV) - A national autism advocate is speaking in Little Rock about autism, what it is, and how to address it in your family. Temple Grandin, is a source of inspiration for those with autism and their families. Grandin is an autism activist who was diagnosed with the disorder at age 2. She's also one of the nation's foremost experts on the treatment of livestock and says she remembers what it was like to grow up autistic. "When I was little kid I couldn't talk. I can remember the frustrations of not being able to talk. I had extremely good early education and early intervention. I can't emphasize enough develop the child's strength," says Grandin. Grandin, who designed curved chutes and other systems for cattle handling, worries other autistic children won't get those opportunities. That's the message she spoke about Monday in Little Rock. "If you have a 2 or 3 year old child who's not talking worst thing you can do is do nothing. Then you got the kids who are quirky and different and I'm very upset that these schools have taken the hands-on classes out. All the art and woodshop and … Continue reading

Comments Off on Autism advocate Temple Grandin in Arkansas

Great Lakes Center for Autism opens in Kalamazoo; Calley says Southwest Michigan can take lead in treatment

Posted: Published on August 14th, 2012

KALAMAZOO, MI Lt. Gov. Brian Calley set a goal for Southwest Michigan at the grand opening of the Great Lakes Center for Autism Treatment and Research on Monday morning. He'd like to see Southwest Michigan become the best place to serve and treat individuals who have autism. We have the opportunity to be the best and the opportunity to be the center of research that drives toward a cure and produces effective treatments, said Calley, who has a daughter with autism and was applauded at the event for becoming the face of Michigan families who care for a loved one with autism. More than 100 people joined Calley, Residential Opportunities, Inc. chief executive Scott Schrum, Director Lloyd Peterson, Wayne Fuqua, a professor and chairman of Western Michigan University's Department of Psychology and Colleen Allen, the president of the Autism Alliance of Michigan as they cut a red ribbon in front of the doors of the new center. State Sen. Tonya Schuitmaker, State Rep. Sean McCann, State Rep. Margaret O'Brien and Portage Mayor Pete Strazdas also attended the event. The center hopes to serve around 150 children and adolescents a year. Fuqua said the center plans to move in its first … Continue reading

Comments Off on Great Lakes Center for Autism opens in Kalamazoo; Calley says Southwest Michigan can take lead in treatment

Stemgent rakes in $11M, largest round to date

Posted: Published on August 14th, 2012

Cambridge stem cell research company Stemgent Inc. has taken $11.3 million in equity, the largest round to date for the four-and-a-half year old company, according to federal filings. The 40-plus employee company, headquartered in Kendall Square with another research and development site in San Diego, Calif., has filed for more than $40 million in debt and equity investment to date. Most recent is a $6.3 million round in February, which came from eight investors who were not listed on the filing. At the time, CEO Ian Ratcliffe told Mass High Tech that the company would use the new funding to expand its licensed intellectual property around stem cell reagents, as well as expanding its existing operations and product lines. The current filing indicates that the $11.3 million comes from eight backers, with related persons listed as board members Stefan Miltenyi, founder of German biotech; Harold Werner and Augustine Lawlor of HealthCare Ventures LLC of Cambridge; and Ralph Christofferson of Morganthaler Partners of Ohio. No one from the company was available for comment Monday. The companys mission is to support cellular reprogramming research by producing products being designed by stem cell researchers. In January 2010, it launched a custom cell line … Continue reading

Posted in Stem Cell Research | Comments Off on Stemgent rakes in $11M, largest round to date

Chromosomal translocations point the way toward personalized cancer care

Posted: Published on August 14th, 2012

Public release date: 13-Aug-2012 [ | E-mail | Share ] Contact: Garth Sundem garth.sundem@ucdenver.edu University of Colorado Denver A broken chromosome is like an unmoored beansprout circling in search of attachment. If a cell tries to replicate itself with broken chromosomes, the cell will be killed and so it would very much like to find its lost end. Often, it finds a workable substitute: another nearby chromosome. When a broken chromosome attaches to another, or when chromosomes use a similar process to exchange genetic material, you've got a translocation genes end up fused to other genes, encoding a new protein they shouldn't. A recent University of Colorado Cancer Center review in the journal Frontiers of Medicine shows that you also frequently have the cause of cancer and in some cases its cure. "The most famous example is the Philadelphia chromosome the translocation and fusion of genes BCR and ABL that causes chronic myeloid leukemia," says Jing Wang, MD, PhD, University of Colorado Cancer Center investigator and assistant professor of immunology at the CU School of Medicine, the review's author. Other oncogenic translocations include the fusion of genes ALK and EML4 to create what's known as ALK+ non-small cell lung cancer. … Continue reading

Comments Off on Chromosomal translocations point the way toward personalized cancer care

Page 6,602«..1020..6,6016,6026,6036,604..6,6106,620..»